ReviewBiosafety and health2025
Exploring enterovirus pathogenesis and cancer therapy potential through reverse genetics.
Review in Biosafety and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NIR-II aggregation-induced emission sonosensitizer for pyroptosis induction in bladder cancer.Bioactive materials · 2026Article
- Chemically Engineered L. reuteri Delivering αPD-L1 and Gallium Ions via Metal-Phenolic Networks Potentiate Anti-Tumor Immunity and Ferroptosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The Application of Nanomaterials in the Detection of Liver Cancer Biomarkers.International journal of nanomedicine · 2026Review
- Small Biological Fighters Against Cancer: Viruses, Bacteria, Archaea, Fungi, Protozoa, and Microalgae.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decades, oncolytic viruses have emerged as prominent therapeutic agents with significant potential for anticancer treatment. Enteroviruses (EVs) have garnered particular attention due to their specific tropism for various types of tumor cells. The rapid advancement of reverse genetics has enabled its application in the genetic modification of enteroviruses and the investigation of viral infection mechanisms. The utilization of reverse genetics has significantly enhanced our understanding of the infection mechanisms and pathogenesis of enteroviruses, while concurrently facilitating the development of translational therapies related to these viruses. In this review, we summarize the progress in the application of reverse genetics to oncolytic enteroviruses and their potential clinical applications. Specifically, we discuss the characteristics of EVs and the applications of reverse genetics in EV research. We review the utilization of reverse genetics in mechanistic investigations of EVs and in exploring the oncolytic potential of EVs. Further, we discuss the oncolytic roles of specific EVs including EV-A71, coxsackievirus B3 (CV-B3), echovirus 7 (Echo-7), CV-A21, and poliovirus. Our review highlights the advances in oncolytic therapy utilizing EVs with specific tumor tropism, which holds significant potential for immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.